Crizotinib versus standard chemotherapy for MET exon 14 lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This study compares crizotinib to standard chemotherapy for people with advanced (spread) non-small cell lung cancer that has a specific change called MET exon 14 skipping. The goal is to see which treatment works better and how safely it controls the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old and can sign an informed consent form
- Your lung cancer is confirmed as non-small cell lung cancer that has progressed or spread, and you have not had systemic (whole-body) treatment yet
- Your tumor test shows MET exon 14 skipping (confirmed by an accredited lab)
- Your overall health is good enough for treatment (ECOG 0–1) and you are expected to live at least 12 weeks
- You have at least one measurable tumor spot on scans, and you may join if brain metastases are stable
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests whether ALK-targeted drugs can shrink or control advanced squamous cell cancer that has spread. You may be eligible if your tumor has an ALK gene rearrangement and you have not had prior cancer medicines for this stage.
This trial tests a targeted drug (Vebreltinib) combined with standard chemotherapy in people with a specific type of advanced non-squamous lung cancer that has a MET gene change (amplification or overexpression). The goal is to see if this combination works better than chemo alone.
This trial tests a combination of two drugs (tepotinib and ivonescimab) for advanced non-small cell lung cancer patients whose tumors have a specific genetic change called MET exon 14 skipping. The goal is to see if this combination can slow or shrink the cancer.
This trial compares a new targeted pill (SY-3505) to the current standard drug (crizotinib) as a first treatment for people with advanced ALK-positive non-small cell lung cancer (NSCLC). It aims to find out which drug works better and has fewer side effects.
This study compares a new targeted therapy pill (taletrectinib) to standard treatments for people with advanced ROS1-positive lung cancer. The goal is to see if taletrectinib works better at shrinking tumors and delaying cancer growth.
This study tests a new targeted pill (vebreltinib) for people with advanced non-small cell lung cancer that has a specific gene change (MET exon 14 mutation). It is for people who have not had much or any prior treatment. The goal is to see if this medicine can shrink tumors and improve outcomes.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.